glp-1 usage by state Impact: How GLP-1s Are Changing the Diabetes Treatment Paradigm GLP-1 Receptor Agonists in Overweight

In a systematic literature review of randomized controlled trials of GLP-1 based therapy in patients with obesity without T2DM, adverse events were reported in 8096 % of patients treated with liraglutide or semaglutide compared with 6396 % of placebo-treated patients

Beyond their effectiveness in glycemic control, these therapies also promote weight loss, making them beneficial for patients with overweight or obesity alongside type 2 diabetes

Why Researchers Choose GLP-3 RETA Retatrutide has become one of the most closely studied investigational peptides because of its innovative triple receptor agonist mechanism

This decline is a direct result of the entrance of more effective agents including Wegovy (semaglutide), approved in 2021, and Zepbound (tirzepatide), approved in 2023

31.2% achieved at least 25% weight loss

Phase 2 showed 24.2% weight loss at 48 weeks